# Immunocore to present at upcoming investor conferences
Canonical URL: https://biopharmsignal.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-d2bca9c7
Ticker: IMCR
Company: Immunocore Holdings plc
Source: Immunocore Holdings plc
Published: 2026-09-01 11:00 EST
Original Source URL: https://www.immunocore.com/investors/news/press-releases/detail/134/immunocore-to-present-at-upcoming-investor-conferences
## Summary

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September…...

## Article Body
Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September.

Cantor Global Healthcare Conference 2026 Fireside Chat: Thursday, September 10, 2026, at 2:45 p.m. EDT

Morgan Stanley 24 th Annual Global Healthcare Conference Fireside Chat: Monday, September 14, 2026, at 2:35 p.m. EDT

Baird 2026 Global Healthcare Conference Fireside Chat: Tuesday, September 15, 2026, at 12:15 p.m. EDT

H.C. Wainwright 28 th Annual Global Investment Conference 1x1 and small group meetings: Wednesday, September 16, 2026

The presentations will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs​ in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Contact Information

Immunocore

Sébastien Desprez, Vice President Communications T: +44 (0) 7458030732 E: sebastien.desprez@immunocore.com Follow on LinkedIn: @Immunocore

Ryan Baker, Vice President of Investor Relations T: +1 (215) 384-4781 E: ir@immunocore.com

Source: Immunocore Holdings plc Released September 1, 2026
## Recent Company News
- 2026-09-01 11:00 EST — [Immunocore to present at upcoming investor conferences](https://biopharmsignal.com/news/IMCR/immunocore-to-present-at-upcoming-investor-conferences-d2bca9c7) — Source: Immunocore Holdings plc
- 2026-08-06 11:00 EST — [Immunocore reports second quarter financial results and provides a business update](https://biopharmsignal.com/news/IMCR/immunocore-reports-second-quarter-financial-results-and-provides-a-business-upda-ab8c4319) — Source: Immunocore Holdings plc
- 2026-07-30 11:00 EST — [Immunocore to report second quarter 2026 financial results and host call on August 6, 2026](https://biopharmsignal.com/news/IMCR/immunocore-to-report-second-quarter-2026-financial-results-and-host-call-on-augu-527188fc) — Source: Immunocore Holdings plc
- 2026-05-31 12:00 EST — [Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma](https://biopharmsignal.com/news/IMCR/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma) — Source: Immunocore Holdings plc
- 2026-05-06 11:00 EST — [Immunocore reports first quarter financial results and provides a business update](https://biopharmsignal.com/news/IMCR/immunocore-reports-first-quarter-financial-results-and-provides-a-business-update) — Source: Immunocore Holdings plc
## Related News
- 2026-09-09 23:25 EST — IRON — [Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-initial-results-from-restore-pv-phase-2-trial-in-patients-718b0075)
- 2026-09-09 20:17 EST — COO — [CooperCompanies Announces Third Quarter 2026 Results](https://biopharmsignal.com/news/COO/coopercompanies-announces-third-quarter-2026-results-0256684b)
- 2026-09-09 20:15 EST — COO — [CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization](https://biopharmsignal.com/news/COO/coopercompanies-completes-strategic-review-increases-share-repurchase-authorizat-c3b7ff3b)
- 2026-09-09 20:15 EST — NBTX — [NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment](https://biopharmsignal.com/news/NBTX/nanobiotix-participera-la-conf-rence-h-c-wainwright-28th-annual-global-investmen-8b1208fb)
- 2026-09-09 20:15 EST — NBTX — [NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/NBTX/nanobiotix-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-co-bd8b771d)